| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | PHA-665752 | CCLE | pan-cancer | AAC | -0.051 | 0.3 |
| mRNA | Nilotinib | CCLE | pan-cancer | AAC | 0.05 | 0.3 |
| mRNA | Crizotinib | CCLE | pan-cancer | AAC | -0.043 | 0.4 |
| mRNA | RAF265 | CCLE | pan-cancer | AAC | 0.045 | 0.4 |
| mRNA | PLX4720 | CCLE | pan-cancer | AAC | -0.04 | 0.4 |
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | 0.036 | 0.4 |
| mRNA | PD-0332991 | CCLE | pan-cancer | AAC | 0.034 | 0.5 |
| mRNA | TKI258 | CCLE | pan-cancer | AAC | 0.031 | 0.5 |
| mRNA | lapatinib | CCLE | pan-cancer | AAC | 0.025 | 0.6 |
| mRNA | 17-AAG | CCLE | pan-cancer | AAC | 0.024 | 0.6 |